<p>加拿大温哥华，2026 年 2 月 9 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克：CMND），（法兰克福证券交易所：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物科技公司，专注于发现和开发新型神经塑性药物，以解决主要的未得到充分治疗的健康问题。今天，公司宣布了其正在进行的 FDA 批准的 I/IIa 期临床试验第二组的额外积极安全顶线结果，该试验评估了 CMND-100，这是一种公司专有的非致幻性 MEAI 基础口服药物候选者，用于治疗酒精使用障碍（AUD）。</p>
<p>这些进一步的安全数据点是在第二组的另外六名患者成功完成治疗后出现的，之前于 2026 年 1 月 14 日宣布，继续加强了在第一组中建立的令人鼓舞的安全性和耐受性特征。</p>
<p>结果强化了没有严重不良事件和整体良好的耐受性，这与第一组报告的有利结果一致，支持公司数据和安全监测委员会（DSMB）一致批准推进第二组的快速进展。</p>
<p>该 I/IIa 期临床试验是一项多国、多中心研究，旨在评估 CMND-100 在中度至重度 AUD 患者中的安全性、耐受性、药代动力学和初步疗效。第二组在包括约翰霍普金斯大学、特拉维夫索拉斯基医疗中心和哈达萨医疗中心等领先地点进行，在 DSMB 批准后不久完成了全部治疗，进一步强调了对 CMND-100 作为 AUD 潜在创新疗法的安全性特征的持续信心。</p>
<p>“来自第二组的这些额外顶线安全结果进一步验证并强化了我们在第一组观察到的积极特征，” Clearmind Medicine 首席执行官 Adi Zuloff-Shani 博士表示。“没有出现严重不良事件，且耐受性保持良好，我们正在继续为 CMND-100 作为一种潜在安全的非致幻性治疗药物，提供有力证据，以应对酒精使用障碍中显著的未满足需求。”</p>
<p><strong>关于 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家临床阶段的迷幻药物生物科技公司，专注于发现和开发新型迷幻药物，以解决广泛且未得到充分服务的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药物的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
<p>公司的知识产权组合目前由十九个专利家族组成，包括 31 项已授予的专利。公司打算在必要时为其化合物申请额外专利，并将保持机会主义，收购额外的知识产权以扩展其组合。</p>
<p>Clearmind 的股票在纳斯达克以 “CMND” 符号上市交易，在法兰克福证券交易所以 “CWY0” 符号上市交易。</p>
<p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
<p>投资者关系</p>
<p>invest@clearmindmedicine.com</p>
<p>电话：（604）260-1566</p>
<p>美国：CMND@crescendo-ir.com</p>
<p>一般咨询</p>
<p>Info@Clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性声明：</strong></p>
<p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法所定义的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达的变体旨在识别前瞻性声明。例如，公司在讨论 CMND-100 作为潜在创新疗法用于酒精使用障碍的安全性时，使用了前瞻性声明，并且它正在继续为 CMND-100 作为一种潜在安全、非致幻、非心理治疗辅助的治疗方法建立有力证据，以满足酒精使用障碍中显著的未满足需求。前瞻性声明并非历史事实，而是基于管理层当前的期望、信念和预测，其中许多本质上固有不确定性。这些期望、信念和预测是以诚信表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或指示的内容有实质性差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的内容有实质性差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2025 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，则不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和网站链接仅为方便，网站上包含的信息并未被纳入本新闻稿的引用中。Clearmind 对第三方网站的内容不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1URXhNQ00zTkRFMU9USTBJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1URXhNQ00zTkRFMU9USTBJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjU2NTJhNzctNGE5YS00YzI3LWExYmQtNDAxNjc3YTc3ZThjLTUwMDA4NjkzNC0yMDI2LTAyLTA5LWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjU2NTJhNzctNGE5YS00YzI3LWExYmQtNDAxNjc3YTc3ZThjLTUwMDA4NjkzNC0yMDI2LTAyLTA5LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

动态生物技术与基因组 ETF - Invesco

标普全球医疗股指数 ETF - iShares

PRME

<p>Clearmind Medicine Inc. 宣布其正在进行的 CMND-100 临床试验 I/IIa 阶段的安全性结果积极，该药物是一种非致幻的酒精使用障碍（AUD）治疗方案。试验的第二组显示没有严重不良事件，并且保持了良好的耐受性，进一步巩固了第一组建立的良好特征。该试验在多个领先的研究中心进行，包括约翰霍普金斯大学。首席执行官 Dr. Adi Zuloff-Shani 强调了 CMND-100 作为 AUD 安全治疗选择的潜力，满足了该领域显著的未满足需求</p>

<p>Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).</p>
<div class="lb-trans"><p>加拿大温哥华，2026 年 2 月 9 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克：CMND），（法兰克福证券交易所：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物科技公司，专注于发现和开发新型神经塑性药物，以解决主要的未得到充分治疗的健康问题。今天，公司宣布了其正在进行的 FDA 批准的 I/IIa 期临床试验第二组的额外积极安全顶线结果，该试验评估了 CMND-100，这是一种公司专有的非致幻性 MEAI 基础口服药物候选者，用于治疗酒精使用障碍（AUD）。</p>
</div><p>These further safety data points, emerging following the successful completion of treatment in another six patients of the second cohort, previously announced January 14, 2026, continue to strengthen the encouraging safety and tolerability profile previously established in the first cohort.</p>
<div class="lb-trans"><p>这些进一步的安全数据点是在第二组的另外六名患者成功完成治疗后出现的，之前于 2026 年 1 月 14 日宣布，继续加强了在第一组中建立的令人鼓舞的安全性和耐受性特征。</p>
</div><p>The results reinforce no serious adverse events and overall good tolerability, consistent with the favorable results reported from the first cohort, support the rapid progression enabled by the Company’s Data and Safety Monitoring Board’s (DSMB) unanimous approval to advance for the second cohort.</p>
<div class="lb-trans"><p>结果强化了没有严重不良事件和整体良好的耐受性，这与第一组报告的有利结果一致，支持公司数据和安全监测委员会（DSMB）一致批准推进第二组的快速进展。</p>
</div><p>The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The second cohort, conducted across leading sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, achieved full treatment completion shortly after DSMB clearance, underscoring continued confidence in CMND-100’s safety profile as a potential innovative therapy for AUD.</p>
<div class="lb-trans"><p>该 I/IIa 期临床试验是一项多国、多中心研究，旨在评估 CMND-100 在中度至重度 AUD 患者中的安全性、耐受性、药代动力学和初步疗效。第二组在包括约翰霍普金斯大学、特拉维夫索拉斯基医疗中心和哈达萨医疗中心等领先地点进行，在 DSMB 批准后不久完成了全部治疗，进一步强调了对 CMND-100 作为 AUD 潜在创新疗法的安全性特征的持续信心。</p>
</div><p>“These additional topline safety results from the second cohort further validate and reinforce the positive profile we observed in the first cohort,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “With no serious adverse events emerging and strong tolerability maintained, we are continuing to build compelling evidence for CMND-100 as a potentially safe, non-hallucinogenic, not adjunct to psychotherapy, treatment to address the significant unmet needs in alcohol use disorder.”</p>
<div class="lb-trans"><p>“来自第二组的这些额外顶线安全结果进一步验证并强化了我们在第一组观察到的积极特征，” Clearmind Medicine 首席执行官 Adi Zuloff-Shani 博士表示。“没有出现严重不良事件，且耐受性保持良好，我们正在继续为 CMND-100 作为一种潜在安全的非致幻性治疗药物，提供有力证据，以应对酒精使用障碍中显著的未满足需求。”</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家临床阶段的迷幻药物生物科技公司，专注于发现和开发新型迷幻药物，以解决广泛且未得到充分服务的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药物的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知识产权组合目前由十九个专利家族组成，包括 31 项已授予的专利。公司打算在必要时为其化合物申请额外专利，并将保持机会主义，收购额外的知识产权以扩展其组合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND&#34; and the Frankfurt Stock Exchange under the symbol “CWY0.”</p>
<div class="lb-trans"><p>Clearmind 的股票在纳斯达克以 “CMND” 符号上市交易，在法兰克福证券交易所以 “CWY0” 符号上市交易。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>Telephone: (604) 260-1566</p>
<div class="lb-trans"><p>电话：（604）260-1566</p>
</div><p>US: CMND@crescendo-ir.com</p>
<div class="lb-trans"><p>美国：CMND@crescendo-ir.com</p>
</div><p>General Inquiries</p>
<div class="lb-trans"><p>一般咨询</p>
</div><p>Info@Clearmindmedicine.com</p>
<div class="lb-trans"><p>Info@Clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses CMND-100’s safety profile as a potential innovative therapy for alcohol use disorder and how it is continuing to build compelling evidence for CMND-100 as a potentially safe, non-hallucinogenic, not adjunct to psychotherapy, treatment to address the significant unmet needs in alcohol use disorder. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法所定义的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达的变体旨在识别前瞻性声明。例如，公司在讨论 CMND-100 作为潜在创新疗法用于酒精使用障碍的安全性时，使用了前瞻性声明，并且它正在继续为 CMND-100 作为一种潜在安全、非致幻、非心理治疗辅助的治疗方法建立有力证据，以满足酒精使用障碍中显著的未满足需求。前瞻性声明并非历史事实，而是基于管理层当前的期望、信念和预测，其中许多本质上固有不确定性。这些期望、信念和预测是以诚信表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或指示的内容有实质性差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的内容有实质性差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2025 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素变化的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，则不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和网站链接仅为方便，网站上包含的信息并未被纳入本新闻稿的引用中。Clearmind 对第三方网站的内容不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU1URXhNQ00zTkRFMU9USTBJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1MTExMCM3NDE1OTI0IzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjU2NTJhNzctNGE5YS00YzI3LWExYmQtNDAxNjc3YTc3ZThjLTUwMDA4NjkzNC0yMDI2LTAyLTA5LWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MjU2NTJhNzctNGE5YS00YzI3LWExYmQtNDAxNjc3YTc3ZThjLTUwMDA4NjkzNC0yMDI2LTAyLTA5LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial  | CMND Stock News

StockTitan

Prime Medicine

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

Clearmind Medicine

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

生物科技 ETF - VanEck Vectors

医疗业 ETF - Vanguard

基因改革 ETF - ARK

医药突破 ETF - ALPS

Clearmind Medicine 宣布了额外的顶线积极安全性结果，进一步巩固了 CMND-100 在正在进行的 I/IIa 期临床试验中的良好特征 | CMND 股票新闻